Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01362400 · ClinicalTrials.gov registry record · Phase 2
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
NCT01362400: Completed Phase 2 study, sponsored by Infinity Pharmaceuticals.
NCT01362400 is a Phase 2 study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 226 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01362400, a Phase 2 study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the impact of IPI-504 in combination with docetaxel to placebo in combination with docetaxel on life expectancy in patients with Non Small Cell Lung cancer (NSCLC). Docetaxel is an approved chemotherapy for NSCLC. An additional goal of the study is to determine the effect of IPI-504, in combination with docetaxel, verses placebo in, combination with docetaxel, on the growth of cancer
Primary Outcome
To determine the overall survival rate of patients administered IPI-504 plus docetaxel vs. placebo plus docetaxel
Interventions
- DRUG IPI 504 plus Docetaxel
- DRUG Placebo plus Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
What the finished NCT01362400 record still lists
NCT01362400 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% higher).
The record links to 0 conditions, and to 2 interventions - of which IPI 504 plus Docetaxel is the first listed.
NCT01362400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01362400 about?
NCT01362400 is a clinical study titled "A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer". The purpose of this study is to compare the impact of IPI-504 in combination with docetaxel to placebo in combination with docetaxel on life expectancy in patients with Non Small Cell Lung cancer (NSCLC). Docetaxel is an approved chemotherapy for NSCLC. An additional goal of the study is to determin...
What is the current status of trial NCT01362400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2011-05. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01362400?
The interventions under investigation include: IPI 504 plus Docetaxel (DRUG), Placebo plus Docetaxel (DRUG).
Who is sponsoring clinical trial NCT01362400?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01362400's enrollment target sits among peer trials
226 267th of 2000 higher than 1,734 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia